Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 315

1.

The natural history of Vanishing White Matter.

Hamilton EMC, van der Lei HDW, Vermeulen G, Gerver JAM, Lourenço CM, Naidu S, Mierzewska H, Gemke RJBJ, de Vet HCW, Uitdehaag BMJ, Lissenberg-Witte BI; VWM Research Group, van der Knaap MS.

Ann Neurol. 2018 Jul 16. doi: 10.1002/ana.25287. [Epub ahead of print]

PMID:
30014503
2.

A standardized protocol for quantification of saccadic eye movements: DEMoNS.

Nij Bijvank JA, Petzold A, Balk LJ, Tan HS, Uitdehaag BMJ, Theodorou M, van Rijn LJ.

PLoS One. 2018 Jul 16;13(7):e0200695. doi: 10.1371/journal.pone.0200695. eCollection 2018.

3.

Disability Outcome Measures in Phase III Clinical Trials in Multiple Sclerosis.

Uitdehaag BMJ.

CNS Drugs. 2018 Jun 20. doi: 10.1007/s40263-018-0530-8. [Epub ahead of print] Review.

PMID:
29926371
4.

Cost-minimization analysis of alemtuzumab compared to fingolimod and natalizumab for the treatment of active relapsing-remitting multiple sclerosis in the Netherlands.

Piena MA, Heisen M, Wormhoudt LW, Wingerden JV, Frequin STFM, Uitdehaag BMJ.

J Med Econ. 2018 Jul 9:1-9. doi: 10.1080/13696998.2018.1489255. [Epub ahead of print]

PMID:
29911917
5.

The clinical value of the patient-reported multiple sclerosis neuropsychological screening questionnaire.

Nauta IM, Balk LJ, Sonder JM, Hulst HE, Uitdehaag BM, Fasotti L, de Jong BA.

Mult Scler. 2018 May 1:1352458518777295. doi: 10.1177/1352458518777295. [Epub ahead of print]

PMID:
29775164
6.

Fronto-limbic disconnection in patients with multiple sclerosis and depression.

van Geest Q, Boeschoten RE, Keijzer MJ, Steenwijk MD, Pouwels PJ, Twisk JW, Smit JH, Uitdehaag BM, Geurts JJ, van Oppen P, Hulst HE.

Mult Scler. 2018 Mar 1:1352458518767051. doi: 10.1177/1352458518767051. [Epub ahead of print]

PMID:
29587565
7.

Software updates of OCT segmentation algorithms influence longitudinal assessment of retinal atrophy.

Coric D, Petzold A, Uitdehaag BMJ, Balk LJ.

J Neurol Sci. 2018 Apr 15;387:16-20. doi: 10.1016/j.jns.2018.01.020. Epub 2018 Feb 3.

PMID:
29571856
8.

Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS study.

Miller DH, Lublin FD, Sormani MP, Kappos L, Yaldizli Ö, Freedman MS, Cree BAC, Weiner HL, Lubetzki C, Hartung HP, Montalban X, Uitdehaag BMJ, MacManus DG, Yousry TA, Gandini Wheeler-Kingshott CAM, Li B, Putzki N, Merschhemke M, Häring DA, Wolinsky JS.

Ann Clin Transl Neurol. 2018 Jan 30;5(3):346-356. doi: 10.1002/acn3.534. eCollection 2018 Mar.

9.

Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis.

Wijburg MT, Kleerekooper I, Lissenberg-Witte BI, de Vos M, Warnke C, Uitdehaag BMJ, Barkhof F, Killestein J, Wattjes MP.

JAMA Neurol. 2018 Jul 1;75(7):827-833. doi: 10.1001/jamaneurol.2018.0094.

PMID:
29532061
10.

The role of the cerebellum in multiple sclerosis-150 years after Charcot.

Parmar K, Stadelmann C, Rocca MA, Langdon D, D'Angelo E, D'Souza M, Burggraaff J, Wegner C, Sastre-Garriga J, Barrantes-Freer A, Dorn J, Uitdehaag BMJ, Montalban X, Wuerfel J, Enzinger C, Rovira A, Tintore M, Filippi M, Kappos L, Sprenger T; MAGNIMS study group.

Neurosci Biobehav Rev. 2018 Jun;89:85-98. doi: 10.1016/j.neubiorev.2018.02.012. Epub 2018 Feb 23. Review.

PMID:
29477616
11.

Explaining the heterogeneity of functional connectivity findings in multiple sclerosis: An empirically informed modeling study.

Tewarie P, Steenwijk MD, Brookes MJ, Uitdehaag BMJ, Geurts JJG, Stam CJ, Schoonheim MM.

Hum Brain Mapp. 2018 Jun;39(6):2541-2548. doi: 10.1002/hbm.24020. Epub 2018 Feb 21.

12.

Anxiety is more important than depression in MS - Commentary.

de Jong BA, Uitdehaag BM.

Mult Scler. 2018 Apr;24(4):444-445. doi: 10.1177/1352458518756516. Epub 2018 Jan 30. No abstract available.

13.

Disease activity following pregnancy-related discontinuation of natalizumab in MS.

Kleerekooper I, van Kempen ZLE, Leurs CE, Dekker I, Rispens T, Lissenberg-Witte BI, van Munster CEP, de Jong BA, van Oosten BW, Uitdehaag BMJ, Wattjes MP, Killestein J.

Neurol Neuroimmunol Neuroinflamm. 2017 Dec 5;5(1):e424. doi: 10.1212/NXI.0000000000000424. eCollection 2018 Jan.

14.

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.

Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA.

Lancet Neurol. 2018 Feb;17(2):162-173. doi: 10.1016/S1474-4422(17)30470-2. Epub 2017 Dec 21. Review.

PMID:
29275977
15.

Does the presence of multiple sclerosis impact on symptom profile in depressed patients?

Boeschoten RE, Schaakxs R, Dekker J, Uitdehaag BMJ, Beekman ATF, Smit JH, Penninx BWJH, van Oppen P.

J Psychosom Res. 2017 Dec;103:70-76. doi: 10.1016/j.jpsychores.2017.10.006. Epub 2017 Oct 12.

PMID:
29167049
16.

Cognitive rehabilitation and mindfulness in multiple sclerosis (REMIND-MS): a study protocol for a randomised controlled trial.

Nauta IM, Speckens AEM, Kessels RPC, Geurts JJG, de Groot V, Uitdehaag BMJ, Fasotti L, de Jong BA.

BMC Neurol. 2017 Nov 21;17(1):201. doi: 10.1186/s12883-017-0979-y.

17.

Inflammatory natalizumab-associated PML: baseline characteristics, lesion evolution and relation with PML-IRIS.

Wattjes MP, Wijburg MT, van Eijk J, Frequin S, Uitdehaag BMJ, Barkhof F, Warnke C, Killestein J; Dutch-Belgian Natalizumab-Associated PML Study Group.

J Neurol Neurosurg Psychiatry. 2018 May;89(5):535-541. doi: 10.1136/jnnp-2017-316886. Epub 2017 Nov 15.

PMID:
29142146
18.

Asymptomatic spinal cord lesions do not predict the time to disability in patients with early multiple sclerosis.

Dekker I, Sombekke MH, Witte BI, Geurts JJ, Barkhof F, Uitdehaag BM, Killestein J, Wattjes MP.

Mult Scler. 2018 Apr;24(4):481-490. doi: 10.1177/1352458517736147. Epub 2017 Nov 6.

19.

The Arm Function in Multiple Sclerosis Questionnaire was successfully translated to German.

Steinheimer S, Wendel M, Vanbellingen T, Westers LT, Hodak J, Blatter V, Uitdehaag BMJ, Kamm CP.

J Hand Ther. 2018 Jan - Mar;31(1):137-140.e1. doi: 10.1016/j.jht.2017.09.010. No abstract available.

PMID:
29102479
20.

Structure-function relationships in the visual system in multiple sclerosis: an MEG and OCT study.

Tewarie P, Balk LJ, Hillebrand A, Steenwijk MD, Uitdehaag BMJ, Stam CJ, Petzold A.

Ann Clin Transl Neurol. 2017 Jul 25;4(9):614-621. doi: 10.1002/acn3.415. eCollection 2017 Sep.

21.

Diagnostic accuracy of optical coherence tomography inter-eye percentage difference for optic neuritis in multiple sclerosis.

Coric D, Balk LJ, Uitdehaag BMJ, Petzold A.

Eur J Neurol. 2017 Dec;24(12):1479-1484. doi: 10.1111/ene.13443. Epub 2017 Oct 9.

PMID:
28887838
22.

SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts.

Bove R, Chitnis T, Cree BA, Tintoré M, Naegelin Y, Uitdehaag BM, Kappos L, Khoury SJ, Montalban X, Hauser SL, Weiner HL; SUMMIT Consortium.

Mult Scler. 2017 Aug 1:1352458517726657. doi: 10.1177/1352458517726657. [Epub ahead of print]

PMID:
28847219
23.

Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients.

Leurs CE, van Kempen ZL, Dekker I, Balk LJ, Wattjes MP, Rispens T, Uitdehaag BM, Killestein J.

Mult Scler. 2017 Aug 1:1352458517726381. doi: 10.1177/1352458517726381. [Epub ahead of print]

PMID:
28823223
24.

The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability.

LaRocca NG, Hudson LD, Rudick R, Amtmann D, Balcer L, Benedict R, Bermel R, Chang I, Chiaravalloti ND, Chin P, Cohen JA, Cutter GR, Davis MD, DeLuca J, Feys P, Francis G, Goldman MD, Hartley E, Kapoor R, Lublin F, Lundstrom G, Matthews PM, Mayo N, Meibach R, Miller DM, Motl RW, Mowry EM, Naismith R, Neville J, Panagoulias J, Panzara M, Phillips G, Robbins A, Sidovar MF, Smith KE, Sperling B, Uitdehaag BM, Weaver J; Multiple Sclerosis Outcome Assessments Consortium (MSOAC).

Mult Scler. 2017 Aug 1:1352458517723718. doi: 10.1177/1352458517723718. [Epub ahead of print]

25.

Five cases of malignant melanoma during fingolimod treatment in Dutch patients with MS.

Killestein J, Leurs CE, Hoogervorst ELJ, van Eijk J, Mostert JP, van den Eertwegh AJM, Uitdehaag BMJ.

Neurology. 2017 Aug 29;89(9):970-972. doi: 10.1212/WNL.0000000000004293. Epub 2017 Aug 2. No abstract available.

PMID:
28768850
26.

Comparative utility of disability progression measures in PPMS: Analysis of the PROMiSe data set.

Koch MW, Cutter GR, Giovannoni G, Uitdehaag BMJ, Wolinsky JS, Davis MD, Steinerman JR, Knappertz V.

Neurol Neuroimmunol Neuroinflamm. 2017 May 10;4(4):e358. doi: 10.1212/NXI.0000000000000358. eCollection 2017 Jul.

27.

Prognostic factors for long-term outcomes in relapsing-remitting multiple sclerosis.

Traboulsee AL, Cornelisseª P, Sandberg-Wollheim M, Uitdehaag BM, Kappos L, Jongen PJ, Constantinescu CS, di Cantogno EV, Li DK.

Mult Scler J Exp Transl Clin. 2016 Sep 6;2:2055217316666406. doi: 10.1177/2055217316666406. eCollection 2016 Jan-Dec.

28.

Retinal atrophy in relation to visual functioning and vision-related quality of life in patients with multiple sclerosis.

Balk LJ, Coric D, Nij Bijvank JA, Killestein J, Uitdehaag BM, Petzold A.

Mult Scler. 2018 May;24(6):767-776. doi: 10.1177/1352458517708463. Epub 2017 May 17.

29.

Increased connectivity of hub networks and cognitive impairment in multiple sclerosis.

Meijer KA, Eijlers AJC, Douw L, Uitdehaag BMJ, Barkhof F, Geurts JJG, Schoonheim MM.

Neurology. 2017 May 30;88(22):2107-2114. doi: 10.1212/WNL.0000000000003982. Epub 2017 May 3.

PMID:
28468841
30.

Metabolites predict lesion formation and severity in relapsing-remitting multiple sclerosis.

Klauser AM, Wiebenga OT, Eijlers AJ, Schoonheim MM, Uitdehaag BM, Barkhof F, Pouwels PJ, Geurts JJ.

Mult Scler. 2018 Apr;24(4):491-500. doi: 10.1177/1352458517702534. Epub 2017 Apr 13.

PMID:
28406063
31.

Regression-Based Norms for the Symbol Digit Modalities Test in the Dutch Population: Improving Detection of Cognitive Impairment in Multiple Sclerosis?

Burggraaff J, Knol DL, Uitdehaag BMJ.

Eur Neurol. 2017;77(5-6):246-252. doi: 10.1159/000464405. Epub 2017 Mar 21.

32.

Cerebrospinal fluid mtDNA concentration is elevated in multiple sclerosis disease and responds to treatment.

Leurs CE, Podlesniy P, Trullas R, Balk L, Steenwijk MD, Malekzadeh A, Piehl F, Uitdehaag BM, Killestein J, van Horssen J, Teunissen CE.

Mult Scler. 2018 Apr;24(4):472-480. doi: 10.1177/1352458517699874. Epub 2017 Mar 15.

33.

Cognitive impairment in patients with multiple sclerosis is associated with atrophy of the inner retinal layers.

Coric D, Balk LJ, Verrijp M, Eijlers A, Schoonheim MM, Killestein J, Uitdehaag BM, Petzold A.

Mult Scler. 2018 Feb;24(2):158-166. doi: 10.1177/1352458517694090. Epub 2017 Feb 1.

34.

A rare cause for visual symptoms in multiple sclerosis: posterior internuclear ophthalmoplegia of Lutz, a historical misnomer.

Nij Bijvank JA, Balk LJ, Tan HS, Uitdehaag BM, van Rijn LJ, Petzold A.

J Neurol. 2017 Mar;264(3):600-602. doi: 10.1007/s00415-017-8412-4. Epub 2017 Feb 13. No abstract available.

PMID:
28194531
35.

Outcome Measures in Clinical Trials for Multiple Sclerosis.

van Munster CE, Uitdehaag BM.

CNS Drugs. 2017 Mar;31(3):217-236. doi: 10.1007/s40263-017-0412-5. Review.

36.

Increased default-mode network centrality in cognitively impaired multiple sclerosis patients.

Eijlers AJ, Meijer KA, Wassenaar TM, Steenwijk MD, Uitdehaag BM, Barkhof F, Wink AM, Geurts JJ, Schoonheim MM.

Neurology. 2017 Mar 7;88(10):952-960. doi: 10.1212/WNL.0000000000003689. Epub 2017 Feb 8.

PMID:
28179464
37.

Development of a questionnaire measuring instrumental activities of daily living (IADL) in patients with brain tumors: a pilot study.

Oort Q, Dirven L, Meijer W, Sikkes SA, Uitdehaag BM, Reijneveld JC, Taphoorn MJ.

J Neurooncol. 2017 Mar;132(1):145-153. doi: 10.1007/s11060-016-2352-1. Epub 2017 Feb 1.

38.

Natalizumab-associated progressive multifocal leukoencephalopathy is not preceded by elevated drug concentrations.

van Kempen ZL, Leurs CE, Vennegoor A, Wattjes MP, Rispens T, Uitdehaag BM, Killestein J.

Mult Scler. 2017 Jun;23(7):995-999. doi: 10.1177/1352458516684023. Epub 2016 Dec 13.

PMID:
28112019
39.

Subcutaneous interferon β-1a in the treatment of clinically isolated syndromes: 3-year and 5-year results of the phase III dosing frequency-blind multicentre REFLEXION study.

Comi G, De Stefano N, Freedman MS, Barkhof F, Uitdehaag BM, de Vos M, Marhardt K, Chen L, Issard D, Kappos L.

J Neurol Neurosurg Psychiatry. 2017 Apr;88(4):285-294. doi: 10.1136/jnnp-2016-314843. Epub 2016 Dec 30.

40.

Prevalence of depression and anxiety in Multiple Sclerosis: A systematic review and meta-analysis.

Boeschoten RE, Braamse AMJ, Beekman ATF, Cuijpers P, van Oppen P, Dekker J, Uitdehaag BMJ.

J Neurol Sci. 2017 Jan 15;372:331-341. doi: 10.1016/j.jns.2016.11.067. Epub 2016 Nov 30. Review.

PMID:
28017241
41.

Glucocorticoid receptor haplotypes conferring increased sensitivity (BclI and N363S) are associated with faster progression of multiple sclerosis.

Melief J, Koper JW, Endert E, Møller HJ, Hamann J, Uitdehaag BM, Huitinga I.

J Neuroimmunol. 2016 Oct 15;299:84-89. doi: 10.1016/j.jneuroim.2016.08.019. Epub 2016 Sep 3.

PMID:
27725129
42.

Internet-based treatment for depression in multiple sclerosis: A randomized controlled trial.

Boeschoten RE, Dekker J, Uitdehaag BM, Beekman AT, Hoogendoorn AW, Collette EH, Cuijpers P, Nieuwenhuis MM, van Oppen P.

Mult Scler. 2017 Jul;23(8):1112-1122. doi: 10.1177/1352458516671820. Epub 2016 Sep 28.

PMID:
27682229
43.

Measurement properties of the Arm Function in Multiple Sclerosis Questionnaire (AMSQ): a study based on Classical Test Theory.

van Leeuwen LM, Mokkink LB, Kamm CP, de Groot V, van den Berg P, Ostelo RWJG, Uitdehaag BMJ.

Disabil Rehabil. 2017 Oct;39(20):2097-2104. doi: 10.1080/09638288.2016.1213898. Epub 2016 Sep 24.

44.

MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance.

Wijburg MT, Witte BI, Vennegoor A, Roosendaal SD, Sanchez E, Liu Y, Martins Jarnalo CO, Uitdehaag BM, Barkhof F, Killestein J, Wattjes MP.

J Neurol Neurosurg Psychiatry. 2016 Oct;87(10):1138-45. doi: 10.1136/jnnp-2016-313772. Epub 2016 Aug 16.

PMID:
27530808
45.

Prognostic value of the S100B protein in newly diagnosed and recurrent glioma patients: a serial analysis.

Holla FK, Postma TJ, Blankenstein MA, van Mierlo TJM, Vos MJ, Sizoo EM, de Groot M, Uitdehaag BMJ, Buter J, Klein M, Reijneveld JC, Heimans JJ.

J Neurooncol. 2016 Sep;129(3):525-532. doi: 10.1007/s11060-016-2204-z. Epub 2016 Jul 11.

46.

Elevated CSF neurofilament proteins predict brain atrophy: A 15-year follow-up study.

Petzold A, Steenwijk MD, Eikelenboom JM, Wattjes MP, Uitdehaag BM.

Mult Scler. 2016 Aug;22(9):1154-62. doi: 10.1177/1352458516645206. Epub 2016 May 11.

PMID:
27207456
47.

Timing of retinal neuronal and axonal loss in MS: a longitudinal OCT study.

Balk LJ, Cruz-Herranz A, Albrecht P, Arnow S, Gelfand JM, Tewarie P, Killestein J, Uitdehaag BM, Petzold A, Green AJ.

J Neurol. 2016 Jul;263(7):1323-31. doi: 10.1007/s00415-016-8127-y. Epub 2016 May 3.

48.

CSF examination still has value in the diagnosis of MS - NO.

Killestein J, Uitdehaag BM.

Mult Scler. 2016 Jul;22(8):995-7. doi: 10.1177/1352458516641777. Epub 2016 Apr 8. No abstract available.

PMID:
27059062
49.

Power estimation for non-standardized multisite studies.

Keshavan A, Paul F, Beyer MK, Zhu AH, Papinutto N, Shinohara RT, Stern W, Amann M, Bakshi R, Bischof A, Carriero A, Comabella M, Crane JC, D'Alfonso S, Demaerel P, Dubois B, Filippi M, Fleischer V, Fontaine B, Gaetano L, Goris A, Graetz C, Gröger A, Groppa S, Hafler DA, Harbo HF, Hemmer B, Jordan K, Kappos L, Kirkish G, Llufriu S, Magon S, Martinelli-Boneschi F, McCauley JL, Montalban X, Mühlau M, Pelletier D, Pattany PM, Pericak-Vance M, Cournu-Rebeix I, Rocca MA, Rovira A, Schlaeger R, Saiz A, Sprenger T, Stecco A, Uitdehaag BMJ, Villoslada P, Wattjes MP, Weiner H, Wuerfel J, Zimmer C, Zipp F; International Multiple Sclerosis Genetics Consortium. Electronic address: AIVINSON@PARTNERS.ORG, Hauser SL, Oksenberg JR, Henry RG.

Neuroimage. 2016 Jul 1;134:281-294. doi: 10.1016/j.neuroimage.2016.03.051. Epub 2016 Apr 1.

50.

High cumulative JC virus seroconversion rate during long-term use of natalizumab.

Vennegoor A, van Rossum JA, Leurs C, Wattjes MP, Rispens T, Murk JL, Uitdehaag BM, Killestein J.

Eur J Neurol. 2016 Jun;23(6):1079-85. doi: 10.1111/ene.12988. Epub 2016 Mar 27.

PMID:
27018481

Supplemental Content

Loading ...
Support Center